BR9914601A - Inibidor de topoisomerase capturado por lipossoma - Google Patents

Inibidor de topoisomerase capturado por lipossoma

Info

Publication number
BR9914601A
BR9914601A BR9914601-0A BR9914601A BR9914601A BR 9914601 A BR9914601 A BR 9914601A BR 9914601 A BR9914601 A BR 9914601A BR 9914601 A BR9914601 A BR 9914601A
Authority
BR
Brazil
Prior art keywords
topoisomerase inhibitor
liposomes
liposome
captured
topoisomerase
Prior art date
Application number
BR9914601-0A
Other languages
English (en)
Inventor
James Lloyd Slater
Gail T Colbern
Peter K Working
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22301756&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9914601(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alza Corp filed Critical Alza Corp
Publication of BR9914601A publication Critical patent/BR9914601A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A61K9/1278—Post-loading, e.g. by ion or pH gradient

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nanotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Patente de Invenção: "INIBIDOR DE TOPOISOMERASE CAPTURADO POR LIPOSSOMA". é descrita uma composição para administração de uma dose terapeuticamente efetiva de um inibidor de topoisomerase 1 ou inibidor de topoisomerase 1/11. A composição inclui lipossomas tendo uma superfície externa e uma superfície interna definindo compartimentos lipossómicos aquosos, e sendo compostos por um lipídio formador de vesículas e um lipídio formador de vesículas derivatizado com um polímero hidrofílico para formar um revestimento de cadeias poliméricas hidrofílicas em ambos os lados interno e externo dos lipossomas. Capturado nos lipossomas encontra-se o inibidor de topoisomerase em uma concentração de pelo menos cerca de 0,10 <109>mol do medicamento por <109>mol do lipídio.
BR9914601-0A 1998-09-16 1999-10-15 Inibidor de topoisomerase capturado por lipossoma BR9914601A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10467198P 1998-09-16 1998-09-16
PCT/US1999/024228 WO2000023052A1 (en) 1998-09-16 1999-10-15 Liposome-entrapped topoisomerase inhibitors

Publications (1)

Publication Number Publication Date
BR9914601A true BR9914601A (pt) 2001-10-23

Family

ID=22301756

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9914601-0A BR9914601A (pt) 1998-09-16 1999-10-15 Inibidor de topoisomerase capturado por lipossoma

Country Status (18)

Country Link
US (4) US6355268B1 (pt)
EP (1) EP1121102B1 (pt)
JP (1) JP2002527466A (pt)
KR (1) KR100679906B1 (pt)
CN (1) CN1205923C (pt)
AT (1) ATE238039T1 (pt)
AU (1) AU774715B2 (pt)
BR (1) BR9914601A (pt)
CA (1) CA2346879A1 (pt)
DE (1) DE69907243T2 (pt)
DK (1) DK1121102T3 (pt)
ES (1) ES2198970T3 (pt)
IL (1) IL142573A0 (pt)
NO (1) NO20011844D0 (pt)
NZ (1) NZ511112A (pt)
PT (1) PT1121102E (pt)
WO (1) WO2000023052A1 (pt)
ZA (1) ZA200103063B (pt)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9914601A (pt) * 1998-09-16 2001-10-23 Alza Corp Inibidor de topoisomerase capturado por lipossoma
US7311924B2 (en) 1999-04-01 2007-12-25 Hana Biosciences, Inc. Compositions and methods for treating cancer
US7244448B2 (en) * 2000-06-30 2007-07-17 Tekmira Pharmaceuticals Corporation Liposomal antineoplastic drugs and uses thereof
AU780194B2 (en) * 1999-06-24 2005-03-10 Kyowa Hakko Kirin Co., Ltd. Method of regulating leakage of drug encapsulated in liposomes
US20040009229A1 (en) * 2000-01-05 2004-01-15 Unger Evan Charles Stabilized nanoparticle formulations of camptotheca derivatives
WO2001085131A2 (en) * 2000-05-11 2001-11-15 Celator Technologies Inc. Lipid carrier compositions for improved drug retention
US7452550B2 (en) 2000-06-30 2008-11-18 Hana Biosciences, Inc. Liposomal antineoplastic drugs and uses thereof
SK7092003A3 (en) 2000-11-09 2004-06-08 Neopharm Inc SN-38 lipid complexes and methods of use
WO2003030864A1 (en) * 2001-05-29 2003-04-17 Neopharm, Inc. Liposomal formulation of irinotecan
EP1480691A4 (en) 2002-03-05 2007-11-28 Univ State Cleveland AGGLOMERATED PARTICLES FOR THE DISPOSAL OF A MEDICINAL PRODUCT IN AEROSOL FORM
EP1393719A1 (en) * 2002-08-23 2004-03-03 Munich Biotech AG Camptothecin-carboxylate formulations
AU2003296897A1 (en) * 2002-08-20 2004-05-04 Neopharm, Inc. Pharmaceutical formulations of camptothecine derivatives
US20060030578A1 (en) * 2002-08-20 2006-02-09 Neopharm, Inc. Pharmaceutically active lipid based formulation of irinotecan
US20070231379A1 (en) * 2002-08-29 2007-10-04 Slater James L Liposome-entrapped topoisomerase inhibitors
US8980310B2 (en) * 2002-12-31 2015-03-17 Bharat Serums and Vaccines, Ltd. Non-pegylated long-circulating liposomes
KR101133084B1 (ko) * 2002-12-31 2012-04-04 자이더스 비에스브이 파마 프라이빗 리미티드 장기간 순환성 비-페길레이티드 리포좀
EP1608338A1 (en) * 2003-04-02 2005-12-28 Celator Technologies Inc. Pharmaceutical compositions containing active agents having a lactone group and transition metal ions
WO2004089419A1 (ja) * 2003-04-04 2004-10-21 The University Of Tokyo 抗ｍｔ－ｍｍｐモノクローナル抗体含有脂質膜構造体
US20040204435A1 (en) * 2003-04-09 2004-10-14 Joachim Liehr Alternating treatment with topoisomerase I and topoisomerase II inhibitors
US20040247624A1 (en) * 2003-06-05 2004-12-09 Unger Evan Charles Methods of making pharmaceutical formulations for the delivery of drugs having low aqueous solubility
EP1643972A4 (en) * 2003-06-27 2010-01-20 Smithkline Beecham Corp STABILIZED LIPOSOMAL TOPOTECAN COMPOSITION AND METHOD
CN100431525C (zh) * 2003-07-17 2008-11-12 台湾东洋药品工业股份有限公司 脂质体悬浮液制造方法及含该法所制脂质体悬浮液的产物
US7196145B2 (en) 2003-08-26 2007-03-27 Smithkline Beecham Corporation Heterofunctional copolymers of glycerol and polyethylene glycol, their conjugates and compositions
JP2007533647A (ja) * 2003-10-24 2007-11-22 アルザ・コーポレーシヨン 脂質粒子の調製
CN100423778C (zh) * 2003-11-25 2008-10-08 上海复旦张江生物医药股份有限公司 用于上载抗肿瘤药物的脂质体载体及其制备方法和应用
WO2005053643A1 (ja) * 2003-12-01 2005-06-16 Mitsubishi Pharma Corporation リポソーム
US20050129750A1 (en) * 2003-12-15 2005-06-16 Yu-Fang Hu Process for producing liposome suspension and product containing liposome suspension produced thereby
US20050129752A1 (en) * 2003-12-15 2005-06-16 Tty Biopharm Limited Company Use and manufacturing process for liposomal doxorubicin pharmaceutical composition
EP1547582A1 (en) * 2003-12-23 2005-06-29 MediGene Oncology GmbH Method of producing lipid complexed camptothecin-carboxylate
EP1547580A1 (en) * 2003-12-23 2005-06-29 MediGene Oncology GmbH Loading of a camptothecin drug into colloidal nanoparticles
KR101245990B1 (ko) 2004-03-26 2013-03-20 테루모 가부시키가이샤 리포솜 제제
US7713517B2 (en) 2004-04-21 2010-05-11 Marval Biosciences, Inc. Compositions and methods for enhancing contrast in imaging
US8357351B2 (en) 2004-04-21 2013-01-22 Ananth Annapragada Nano-scale contrast agents and methods of use
CA2928387A1 (en) 2004-05-03 2005-11-17 Merrimack Pharmaceuticals, Inc. Drug delivery liposomes containing anionic polyols or anionic sugars
AU2011202665C1 (en) * 2004-05-03 2014-04-24 Ipsen Biopharm Ltd. Liposomes useful for drug delivery
US8658203B2 (en) * 2004-05-03 2014-02-25 Merrimack Pharmaceuticals, Inc. Liposomes useful for drug delivery to the brain
JP4885715B2 (ja) * 2004-06-01 2012-02-29 テルモ株式会社 イリノテカン製剤
AU2005253852B2 (en) * 2004-06-18 2008-05-29 Kabushiki Kaisha Yakult Honsha Liposome preparation containing slightly water-soluble camptothecin
US7449196B2 (en) * 2004-07-09 2008-11-11 Robert Sabin Anti tumor compositions and methods of use
EP1614414A3 (en) 2004-07-09 2008-07-09 Robert Sabin Compositions comprising a copper compound for treatment of mammalian diseases
JP4433918B2 (ja) * 2004-07-15 2010-03-17 コニカミノルタエムジー株式会社 画像形成方法
US8318200B1 (en) * 2004-10-05 2012-11-27 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
US8318198B1 (en) * 2004-10-05 2012-11-27 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
US8663599B1 (en) * 2004-10-05 2014-03-04 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
AU2005302255A1 (en) * 2004-10-28 2006-05-11 Alza Corporation Lyophilized liposome formulations and method
TW200618820A (en) * 2004-11-05 2006-06-16 Alza Corp Liposome formulations of boronic acid compounds
US20090285878A1 (en) * 2004-11-05 2009-11-19 Tekmira Pharmaceuticals Corporation Compositions and methods for stabilizing liposomal drug formulations
KR100651728B1 (ko) * 2004-11-10 2006-12-06 한국전자통신연구원 정착기를 갖는 전자 소자용 화합물 및 이를 포함하는 전자소자와 이들의 제조 방법
JP5110880B2 (ja) * 2004-11-18 2012-12-26 テルモ株式会社 医薬組成物、製剤および組み合わせ製剤
US20090104254A1 (en) * 2004-12-22 2009-04-23 Rutgers, The State University Of New Jersey Controlled Release Hydrogels
WO2007106549A2 (en) * 2006-03-15 2007-09-20 Alza Corporation Method for treating brain cancer
US20070259031A1 (en) * 2006-04-26 2007-11-08 The Regents Of The University Of California Compositions and methods for convection enhanced delivery of high molecular weight neurotherapeutics
US20080081051A1 (en) * 2006-09-28 2008-04-03 Robert Sabin Method of manufacturing anti-tumor and anti-viral compositions
BRPI0717800A2 (pt) * 2006-10-06 2014-09-09 Politechnic Inst Univ New York COMPOSIÇÃO DE LIPOSSOMAS SENSÍVEIS AO pH
US20100047334A1 (en) * 2006-10-06 2010-02-25 Sofou Stavroula Ph sensitive liposome compositions for controlling surface topography and binding reactivity in functionalized liposomes
JP5080779B2 (ja) * 2006-10-25 2012-11-21 テルモ株式会社 リポソーム製剤の製造方法
WO2008070009A2 (en) * 2006-12-01 2008-06-12 Alza Corporation Treating solid tumors and monocytic leukemia using topoisomerase inhibitors in liposomes
EP1932517A3 (en) * 2006-12-11 2008-07-16 Universiteit Utrecht Holding B.V. Liposomes containing a polyphenol derivative such as caffeic acid and a method of post-loading thereof
WO2008079240A1 (en) * 2006-12-19 2008-07-03 Alza Corporation Use of liposome-entrapped agents for treating tumors
CN101209243B (zh) 2006-12-29 2010-12-08 石药集团中奇制药技术（石家庄）有限公司 一种脂质体药物及其制备方法
CA2676986A1 (en) * 2007-02-01 2008-08-07 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Pharmaceutical composition comprising a campothecin derivative
JP2011506325A (ja) 2007-12-05 2011-03-03 マーバル バイオサイエンシーズ インコーポレイテッド ナノスケールのコントラスト剤及びその使用方法
DE102008036227A1 (de) * 2008-08-02 2010-02-04 Volkswagen Ag Verstellkinematik für eine Armlehne
CN101601642A (zh) * 2009-06-30 2009-12-16 沈阳药科大学 一种囊泡类给药系统及其应用
CN102596178B (zh) 2009-10-26 2014-12-03 石药集团中奇制药技术（石家庄）有限公司 具有磺丁基醚环糊精盐内水相的脂质体
US11357728B2 (en) 2009-10-26 2022-06-14 Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. Liposome having inner water phase containing sulfobutyl ether cyclodextrin salt
PT2508170E (pt) * 2009-12-03 2015-10-16 Shanghai Hengrui Pharm Co Ltd Lipossoma de irinotecano ou o seu cloridrato e seu método de preparação
US20110237686A1 (en) 2010-03-26 2011-09-29 Cerulean Pharma Inc Formulations and methods of use
WO2012118376A1 (en) * 2011-03-01 2012-09-07 To-Bbb Holding B.V. Advanced active liposomal loading of poorly water-soluble substances
AU2013202947B2 (en) 2012-06-13 2016-06-02 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
US9717724B2 (en) 2012-06-13 2017-08-01 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies
CN103655477B (zh) * 2012-09-03 2017-06-23 唐为钢 一种恩替卡韦高密度脂蛋白包封制剂及其制备方法和用途
US9801874B2 (en) 2012-11-20 2017-10-31 Spectrum Pharmaceuticals Method for the preparation of liposome encapsulated vincristine for therapeutic use
US10220095B2 (en) * 2013-03-15 2019-03-05 Taiwan Liposome Company, Ltd Controlled drug release liposome compositions and methods thereof
WO2014179760A1 (en) 2013-05-03 2014-11-06 The Regents Of The University Of California Cyclic di-nucleotide induction of type i interferon
WO2015061206A2 (en) 2013-10-21 2015-04-30 North Carolina State University Methods and constructs for compound delivery
CN104367550A (zh) * 2014-11-18 2015-02-25 南京华威医药科技开发有限公司 一种贝洛替康长循环纳米脂质体及其制备方法
US11318131B2 (en) 2015-05-18 2022-05-03 Ipsen Biopharm Ltd. Nanoliposomal irinotecan for use in treating small cell lung cancer
US10123973B2 (en) * 2015-06-11 2018-11-13 Mashhad University Of Medical Science Liposome composition for cancer treatment
TWI678213B (zh) 2015-07-22 2019-12-01 美商史倍壯製藥公司 用於長春新鹼硫酸鹽脂質體注射之即可使用的調配物
EP3337467B1 (en) 2015-08-20 2020-12-09 Ipsen Biopharm Ltd. Combination therapy using liposomal irinotecan and a parp inhibitor for cancer treatment
MX385425B (es) 2015-08-21 2025-03-18 Ipsen Biopharm Ltd Irinotecán liposomal y oxaliplatino, 5-fluoroacilo y leucovorina para usarse en el tratamiento de cáncer pancreático metastásico.
JP6495466B2 (ja) * 2015-10-07 2019-04-03 塩水港精糖株式会社 タキサン化合物を内包するリポソーム
MX382522B (es) 2015-10-16 2025-03-13 Ipsen Biopharm Ltd Composiciones farmaceuticas estabilizantes de camptotecina.
EP3535026A1 (en) 2016-11-02 2019-09-11 Ipsen Biopharm Limited Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluoruracil (and leucovorin)
FI3603620T3 (fi) 2017-03-31 2025-12-02 Fujifilm Corp Liposomikoostumus ja farmaseuttinen koostumus
PL3811931T3 (pl) 2018-06-20 2024-11-18 Fujifilm Corporation Skojarzony środek leczniczy zawierający kompozycję liposomową z kapsułkowanym lekiem i inhibitor punktu kontroli immunologicznej
WO2020071349A1 (ja) 2018-10-01 2020-04-09 富士フイルム株式会社 薬物を内包するリポソーム組成物およびプラチナ製剤を含む組合せ医薬
JPWO2022250015A1 (pt) 2021-05-24 2022-12-01
TW202313031A (zh) 2021-05-24 2023-04-01 日商富士軟片股份有限公司 抗腫瘤劑

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1270198A (en) * 1984-08-08 1990-06-12 Marcel B. Bally Encapsulation of antineoplastic agents in liposomes
US5244903A (en) 1987-03-31 1993-09-14 Research Triangle Institute Camptothecin analogs as potent inhibitors of topoisomerase I
IL91664A (en) 1988-09-28 1993-05-13 Yissum Res Dev Co Ammonium transmembrane gradient system for efficient loading of liposomes with amphipathic drugs and their controlled release
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
DE4119981C1 (pt) 1991-06-18 1993-01-21 Fa. Carl Freudenberg, 6940 Weinheim, De
US5552156A (en) 1992-10-23 1996-09-03 Ohio State University Liposomal and micellular stabilization of camptothecin drugs
US5395619A (en) 1993-03-03 1995-03-07 Liposome Technology, Inc. Lipid-polymer conjugates and liposomes
WO1994026253A1 (en) 1993-05-19 1994-11-24 The Liposome Company, Inc. Liposome having a multicomponent bilayer which contains a bioactive agent as an integral component of the bilayer
JPH09504517A (ja) 1993-09-27 1997-05-06 スミスクライン・ビーチャム・コーポレイション カンプトテシン処方物
CA2263455C (en) 1996-08-23 2002-10-29 Sequus Pharmaceuticals, Inc. Liposomes containing a cisplatin compound
TW520297B (en) * 1996-10-11 2003-02-11 Sequus Pharm Inc Fusogenic liposome composition and method
US6056973A (en) * 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
CA2269758C (en) 1996-10-22 2008-01-08 Hermes Biosciences, Inc. Liposome compositions comprising ionizable compounds in stable precipitated form and methods for their preparation
US5837282A (en) 1996-10-30 1998-11-17 University Of British Columbia Ionophore-mediated liposome loading
WO1999013816A2 (en) * 1997-09-16 1999-03-25 Nexstar Pharmaceuticals, Inc. Liposomal camptothecin formulations
BR9914601A (pt) * 1998-09-16 2001-10-23 Alza Corp Inibidor de topoisomerase capturado por lipossoma

Also Published As

Publication number Publication date
DE69907243D1 (de) 2003-05-28
NO20011844L (no) 2001-04-10
KR20010075639A (ko) 2001-08-09
JP2002527466A (ja) 2002-08-27
CN1205923C (zh) 2005-06-15
CA2346879A1 (en) 2000-04-27
EP1121102A1 (en) 2001-08-08
CN1323199A (zh) 2001-11-21
US6355268B1 (en) 2002-03-12
US7244449B2 (en) 2007-07-17
ZA200103063B (en) 2001-10-18
PT1121102E (pt) 2003-09-30
DK1121102T3 (da) 2003-08-11
NZ511112A (en) 2003-11-28
EP1121102B1 (en) 2003-04-23
ES2198970T3 (es) 2004-02-01
AU1118900A (en) 2000-05-08
US6465008B1 (en) 2002-10-15
ATE238039T1 (de) 2003-05-15
US20020146450A1 (en) 2002-10-10
US20050106231A1 (en) 2005-05-19
IL142573A0 (en) 2002-03-10
US7279179B2 (en) 2007-10-09
KR100679906B1 (ko) 2007-02-07
WO2000023052A1 (en) 2000-04-27
AU774715B2 (en) 2004-07-08
US20030133973A1 (en) 2003-07-17
DE69907243T2 (de) 2004-02-19
NO20011844D0 (no) 2001-04-10

Similar Documents

Publication Publication Date Title
BR9914601A (pt) Inibidor de topoisomerase capturado por lipossoma
ATE252372T1 (de) Liposome enthaltend cisplatin
PT1083881E (pt) Composicao de liposomas contendo um derivado de quinolona e uso da mesma como agente antibacteriano
PT932391E (pt) Composicao lipossomal fusogenica e metodo
AU6368494A (en) Enhanced circulation effector composition and method
ATE288743T1 (de) Pharmazeutische trägervorrichtung welche zur verabreichung von wirkstoffen an schleimhautoberflächen geeignet ist
TR200101138T2 (tr) Tedavi edici ajanlar ihtiva eden kaviteli implant
CA2308513A1 (en) Method and composition for delivering zinc to the nasal membrane
PE13699A1 (es) Articulo absorbente con alta rigidez
ES2130420T3 (es) Preparado transdermico de sustancia activa.
ATE378060T1 (de) Verbessertes angereichertes blutplättchen wundheilmittel
BR0002688A (pt) Camada de revestimento e uma camada de transferência de absorvente combinados
EP1140022B8 (en) Method of administering a compound to multi-drug resistant cells
FR2774288B1 (fr) Microgranules d&#39;omeprazole gastroproteges, procede d&#39;obtention et preparations pharmaceutiques
ES2087255T3 (es) Composicion polimera para la fabricacion de una pelicula desprendible.
DK324687A (da) Transdermalt farmeceutisk praeparat
CA2327693A1 (en) Use of phospholipids for the manufacture of a medicament for the prevention of adhesions
FI960850A7 (fi) Kinoksaliinien käyttö proteaasi-inhibiittoreihin yhdistettyinä lääkkeeksi AIDS:in ja/tai HIV-tartuntojen hoitamiseksi
ES2174533T3 (es) Uso de una mezcla de un diol y un acido alfa-hidroxi para el tratamiento de enfermedades de la piel hiperqueratoticas.
DE69635806D1 (de) Diphosphonat derivate von therapeutisch wirksamen stoffen
ES2092559T3 (es) Formulacion farmaceutica que contiene penciclovir.
DE59510583D1 (de) Pharmazeutische zusammensetzung zur systemischen transdermalen verabreichung mit dem wirkstoff morphin-6-glucuronid
CO4600680A1 (es) Procedimientos para la prevencion de la degradacion de la proteina c
AU4975700A (en) Absorbent article comprising topsheet with low surfactant or no synthetic surfactant
CO4750616A1 (es) Hilo dental

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PRESENTE PEDIDO DE ACORDO COM ART. 8O, 13, 24 E 25 DA LPI.

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.